These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 12901947

  • 1. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK, Frost P.
    Curr Opin Pharmacol; 2003 Aug; 3(4):386-90. PubMed ID: 12901947
    [Abstract] [Full Text] [Related]

  • 2. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK.
    Expert Opin Biol Ther; 2004 Sep; 4(9):1445-52. PubMed ID: 15335312
    [Abstract] [Full Text] [Related]

  • 3. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
    DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK.
    Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
    [Abstract] [Full Text] [Related]

  • 4. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD.
    Clin Cancer Res; 2011 Oct 15; 17(20):6417-27. PubMed ID: 22003069
    [Abstract] [Full Text] [Related]

  • 5. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
    DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK.
    Blood; 2004 Mar 01; 103(5):1807-14. PubMed ID: 14615373
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
    Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS.
    J Clin Pharmacol; 2001 Nov 01; 41(11):1206-14. PubMed ID: 11697753
    [Abstract] [Full Text] [Related]

  • 7. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
    Petrich T, Korkmaz Z, Krull D, Frömke C, Meyer GJ, Knapp WH.
    Eur J Nucl Med Mol Imaging; 2010 May 01; 37(5):851-61. PubMed ID: 20107790
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives.
    Sperr WR, Florian S, Hauswirth AW, Valent P.
    Leuk Lymphoma; 2005 Aug 01; 46(8):1115-20. PubMed ID: 16085551
    [Abstract] [Full Text] [Related]

  • 10. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
    Duong HK, Sekeres MA.
    Clin Interv Aging; 2009 Aug 01; 4():197-205. PubMed ID: 19503782
    [Abstract] [Full Text] [Related]

  • 11. Eradication of CD19+ leukemia by targeted calicheamicin θ.
    Bernt KM, Prokop A, Huebener N, Gaedicke G, Wrasidlo W, Lode HN.
    Bioconjug Chem; 2009 Aug 19; 20(8):1587-94. PubMed ID: 19572629
    [Abstract] [Full Text] [Related]

  • 12. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
    Stasi R.
    Expert Opin Biol Ther; 2008 Apr 19; 8(4):527-40. PubMed ID: 18352855
    [Abstract] [Full Text] [Related]

  • 13. [Immunoconjugates, drug-armed antibodies to fight against cancer].
    Haeuw JF, Caussanel V, Beck A.
    Med Sci (Paris); 2009 Dec 19; 25(12):1046-52. PubMed ID: 20035677
    [Abstract] [Full Text] [Related]

  • 14. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
    Dijoseph JF, Dougher MM, Armellino DC, Kalyandrug L, Kunz A, Boghaert ER, Hamann PR, Damle NK.
    Cancer Immunol Immunother; 2007 Jul 19; 56(7):1107-17. PubMed ID: 17160682
    [Abstract] [Full Text] [Related]

  • 15. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M, Kano Y, Akutsu M, Tsunoda S, Izumi T, Yazawa Y, Miyawaki S, Mano H, Furukawa Y.
    Anticancer Res; 2009 Nov 19; 29(11):4589-96. PubMed ID: 20032408
    [Abstract] [Full Text] [Related]

  • 16. Bioweapons of tumor mass destruction?
    Dyer MJ.
    J Clin Oncol; 2003 Aug 15; 21(16):3011-2. PubMed ID: 12837808
    [No Abstract] [Full Text] [Related]

  • 17. CD22-directed monoclonal antibody therapy for lymphoma.
    Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP.
    Semin Oncol; 2003 Aug 15; 30(4):457-64. PubMed ID: 12939714
    [Abstract] [Full Text] [Related]

  • 18. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ.
    Expert Rev Anticancer Ther; 2002 Dec 15; 2(6):630-40. PubMed ID: 12503209
    [Abstract] [Full Text] [Related]

  • 19. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
    Linenberger ML.
    Leukemia; 2005 Feb 15; 19(2):176-82. PubMed ID: 15592433
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.